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Abstract
Background: Macrophages can produce vascular endothelial growth factor (VEGF) in response
to hypoxia, transforming growth factor β1 (TGF-β1), angiotensin II, basic fibroblast growth factor
(bFGF), and interleukin-1. These factors have been found in the serum of coronary artery disease
(CAD) patients as well as in atherosclerotic lesions. The aim of the present study was to test the
hypothesis that the expression of VEGF, TGF-β1 and bFGF in peripheral monocytes and
lymphocytes is related to CAD.
Methods: Human Mononuclear cells and lymphocytes from peripheral blood were isolated from
53 donors undergoing angiography. Seventeen were found to be healthy and 36 were diagnosed
with CAD. The respective mRNAs were extracted and quantified.
Results: The statistical analysis revealed a significant increase of the basal level expression for
macrophage VEGF and bFGF in the CAD SA (stable angina) patient group compared to the noCAD
(control) (p = 0.041 and p = 0.022 respectively) and CAD UA (unstable angina) (p = 0.024 and p =
0.005 respectively) groups, which was highly dependent on the diabetic status of the population.
Furthermore, we demonstrated with an in vitro cell culture model that the levels of VEGF and
bFGF in monocytes of healthy donors are not affected by short term exposure to increased glucose
levels (usually observed in the diabetic patients) and/or statin.
Conclusion: Our findings display a statistically significant association of the increased VEGF and
bFGF levels in peripheral monocytes, with stable angina and diabetes in coronary artery disease.
The results give new insight to CAD and the impaired collateral vessel formation in diabetics.
Background
Association of cardiovascular disease with several risk fac-
tors such as smoking, hypertension, hypercholesterolae-
mia, diabetes and family history is well established [1].
However, the critical molecular and cellular interactions
that lead to the development, growth and rupture of
atherosclerotic lesions remain to be identified. Monocyte
derived macrophages are believed to play a pivotal role in
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the initiation and progression of atheroma formation. The
differentiation state of macrophages is directly related to
macrophage metabolism of lipoproteins and cholesterol
and consequently foam cell formation [2]. Progression of
atherosclerosis relates to accumulation of macrophages,
alteration of EC (endothelial cell) function, phenotypic
modulation of SMCs (smooth muscle cell), and neovascu-
larization of the plaque tissue [3,4]
A secondary to atherosclerosis event, also involving mac-
rophages, is the process of collateral vessel development
(arteriogenesis) which appears under hypoxic stress [5].
Arteriogenesis is beneficial to patients with CAD (coro-
nary artery disease) where stenosis or occlusion causes
repetitive or chronic regional myocardial ischemia [6].
Following the occlusion of a large artery, the stress of
ischemia causes nearby arterioles to become activated.
Their endothelial surface upregulates expression of adhe-
sion molecules [7] and triggers the initial monocyte inva-
sion into the arterial wall of the growing collateral
arteriole. The proposed model [8] states that the infiltrat-
ing monocytes/macrophages produce VEGF (vascular
endothelial growth factor), bFGF (basic fibroblast growth
factor) and other factors which act on both the endothe-
lium and the smooth muscle cells thereby inducing more
VEGF production from these cells. Additional migration
of monocytes is facilitated by the secretion of several
growth factors including VEGF, bFGF and MCP-1 (mono-
cyte chemoattractant protein 1). Arteriogenesis has been
shown to vary between individuals [9] and it was defective
in diabetic individuals where the migratory response of
monocytes to VEGF was attenuated [10].
Modified low density lipoproteins, proinflammatory
cytokines and chemotactic factors are known to affect the
differentiation and migration status of macrophages and
thus play a role in the macrophage mediated atherogene-
sis in the vascular wall [3] and collateral vessel formation
[8]. Macrophages can produce VEGF in response to
hypoxia, TGF-β1, angiotensin II, bFGF, and interleukin-1
[11,12]. These factors have also been found to be
expressed in atherosclerotic lesions.
CAD patients receive standard medication which among
other compounds includes statins. HMG-CoA reductase
inhibition by statins as established drugs for the treatment
of hypercholesterolaemia [13] has been associated with
beneficial effects on the progression and regression of
atherosclerosis in humans and in animal models [14,15].
Statins have been reported to influence the surface pheno-
type of peripheral lymphocytes [16].
Atherogenesis is believed to be a system-wide inflamma-
tory response. As such, all peripheral lymphocytes and
monocytes could be affected. Although VEGF, bFGF and
TGF-β1 are involved in the mechanism of atherogenesis
and collateral vessel development, a detailed analysis of
the steady state mRNA levels of these factors in isolated
peripheral monocyte and lymphocyte populations of
patients with CAD has not been previously performed.
The aim of the present study was to test the hypothesis
that the expression levels of VEGF, TGF-β1 and bFGF in
peripheral monocytes and lymphocytes is related to CAD.
We also tested the effect of clinical parameters related to
CAD (diabetes, type of myocardial ischemic episodes) on
the above relationship. The strategy involved exploring
the expression levels of VEGF, TGF-β1 and bFGF in puri-
fied peripheral monocytes and lymphocytes from patients
with CAD and normal donors. We observed a significant
increase of VEGF and bFGF but not TGF-β1 in CAD
patients with stable angina, which is even more pro-
nounced in the diabetics. Furthermore we demonstrated
with an in vitro cell culture model that the short term effect
of glucose and/or statins, which are usually observed in
the diabetic CAD patients, did not increase the levels of
VEGF and bFGF on monocytes from healthy donors.
Methods
Patients
Patients were recruited randomly from those undergoing
diagnostic catheterization at the University Hospital (Her-
aklion, Crete, Greece) over a 4 month period. A total of 53
patients were included in the study. A group of 36
patients, that were submitted to angiography due to
angina pectoris, showed ≥ 1 vessel coronary stenosis of ≥
70% by visual analysis and thus were considered as CAD
group. A total of 17 individuals, that were submitted to
angiography due to valvular disease or nontypical chest
pain syndrome with a negative or non diagnostic exercise
ECG or asymptomatic episodes of unsustained ventricular
tachycardia, were found to have no stenosis and were con-
sidered to be the control group (noCAD). Due to poor
RNA yields we excluded from the analysis 4 macrophage
(1 CAD UA, 2 noCAD and 1 CAD SA) and 12 lymphocyte
samples (5 CAD UA, 3 noCAD and 4 CAD SA).
The patients, and controls had no evidence of peripheral
artery or cerebrovascular disease; all had normal echo-
duplex of cervical arteries, the aorta and lower limb arter-
ies and/or resting and post-exercise ankle/ brachial pres-
sure index > 0.85. Criteria for exclusion were 1) age <
18.2) clinical or laboratory signs of acute or chronic
inflammatory disease and 3) presence of overt neoplastic
disease.
The definitions of the clinical parameters used in the
study are presented below. A.  Hypertension: systolic
blood pressure ≥ 160 mm Mg and or diastolic > 90 mm
Mg,  B.  Hypercholesterolaemia: LDL ≥ 160 mg/dl for
patient without any artery risk factors for coronary arteryJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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desease or LDL ≥ 130 mg/dl for patient with one known
risk factor for coronary artery desease or LDL ≥ 100 mg/dl
for patent with known coronary artery desease, C. Diabe-
tes: Two separate values of fasting blood glucose ≥ 126
mg/dl or two random values of blood glucose ≥ 200 mg/
dl. D. Levels of acid uric ≥ 7 mg/dl. E. Unstable angina:
crescendo angina of superimposed on a preexisting pat-
tern of relatively stable exertion-related angina pectoris or
angina pectoris at rest as well as with minimal exertion or
angina pectoris of new onset which is brought on by min-
imal exertion. F. Stable angina: stable angina on effort
without any clinical changes within two months. The
present study was approved by the institutional ethics
committee and the patients gave written informed con-
sent to participate in the study. The investigation con-
forms to the principles outlined in the Declaration of
Helsinki.
Blood collection, lymphocyte separation and cell culture
Twenty millilitres of blood was collected from the femoral
venous catheter placed for the catheterization before ang-
iography was begun. The blood was immediately placed
in four 5-ml polypropylene heparinized tubes and kept
on ice until it was used for monocyte isolation. In all
instances, the blood was used within 1 hour of removal
from the patients.
The 20 ml of heparinized blood was gently layered over
30 ml of Histopaque-1077 (Sigma) in a 50-ml polypro-
pylene centrifuge tube. Tubes were centrifuged at 1800
rpm for 30 minutes at room temperature. The middle
phase (buffy coat) containing the monocytes was isolated
and placed in a fresh 50-ml polypropylene centrifuge
tube. The cell yield was on average 106 cells /ml of blood.
The isolated mononuclear cells were washed twice with
sterile phosphate buffered saline (PBS). The cell pellets
were resuspended in RPMI1640 medium (Sigma). The
cells were plated on 25 cm2 tissue culture flasks (Costar)
and incubated in a 5% CO2 incubator (Forma) at 37°C for
1 hour to allow for monocyte attachment. The non adher-
ent cells were removed by washing twice with PBS. Purity
assessment of the monocyte preparation was performed
with anti CD14 FACS analysis (FACSCalibur, Beckton
Dickinson) and showed consistently more than 95%
purity. The lymphocyte fraction mentioned in the study
represented the non adherent fraction of the ficoll puri-
fied peripheral leucocyte preparation. The lymphocyte
fraction contained a very low level of granulocytes (<1%)
and macrophages (<1%). The viability of our populations
after the purification procedure was more than 99% as
determined by trypan blue exclusion.
Analysis of the effect of glucose and Fluvastatin on the
kinetics of mRNA expression was performed as previously
described [17]. Due to the need of a large cell number for
the kinetic analysis we utilized buffy coats from healthy
donors. Briefly Ficoll purified cells were incubated in 6-
well plates (Costar) at a concentration of 2 × 106 cells/ml,
in 2 ml RPMI1640 medium, for 1 hour, in a CO2 incuba-
tor. Non adherent cells were removed by washing twice
with PBS and new RPMI1640 medium was added con-
taining 5% human serum. Fluvastatin (1 µM) or glucose
(6 mg/ml) was added according to the study design. At an
appropriate time period (30 min, 1 h, 2 h, 4 h, 24 h, 48 h)
cells were harvested and mRNA was extracted and
purified.
Extraction and quantification of mRNA
Total RNA was isolated directly from the tissue culture
dishes containing the adherent monocytes using the Tri-
zol reagent (Life Technologies Ltd., U.K.). Briefly, 1 ml of
reagent was added to each dish with vigorous pipetting
and transferred to a 1.5 ml Eppendorf tube. Chloroform
(200 µl) was added, and the tube was vortexed and centri-
fuged at 14 000 rpm for 15 minutes. The RNA was precip-
itated with an equal volume of isopropanol and washed
with 75% ethanol. The RNA was air-dried and resus-
pended in water treated with diethyl pyrocarbonate. The
RNA preparation was treated with DNase I to remove
residual traces of DNA, purified with the phenol-Chloro-
form method and precipitated with ethanol. The non-
adherent/lymph fraction was harvested, centrifuged and
RNA extraction was performed with the Trizol reagent
according to the manufacturer's instructions. RNA con-
centration and purity was determined on a UV spectro-
photometer (Hitachi Instruments Inc., U.S.A.) by the 260
nm absorbance and 260 nm to 280 nm absorbance ratio
respectively. 1% agarose gel electrophoresis and ethidium
bromide staining were used to examine RNA integrity.
Semi-quantitative RT-PCR
Each quantification set included two PCR reactions (the
target and the β2-microglobulin (β2M) reference). Each
PCR reaction (target and β2M) was optimized individu-
ally for primer, Mg and Taq polymerase concentration
using as a template a representative pool of all samples to
be measured. Then the reactions were combined into a
single tube in order to eliminate tube to tube variations. A
new optimization was performed to ensure that there was
no cross inhibition between the two PCR reactions. Sub-
sequently another optimization was performed modulat-
ing the relative concentration of the two sets of primers to
ensure that the two reactions reached the logarithmic
phase of expansion in the same PCR cycles (reaction syn-
chronization). Finally we determined the cycle in which
the reaction reached the middle of the logarithmic expan-
sion phase. The set of conditions that were established
regarding primer, Mg, Taq polymerase concentration and
cycle number, was applied specifically to the set of sam-
ples that were used for the standardization (sample pool)Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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and the corresponding target. The total standardization
procedure was repeated for each quantification reaction
(bFGF, VEGF, TGF-β1).
Reverse transcription reactions for the preparation of first
strand cDNA from 1 µg of total RNA, were performed for
1 h at 52°C, using 15 U Thermoscript reverse tran-
scriptase, 40 U RNaseOut, 50 ng of random hexamers and
1.0 mM of each dNTP in a total volume of 20 µl of 1x First
Strand cDNA Synthesis Buffer containing 5 mM dithioth-
reitol (DTT), ensued by incubation for 20 min at 37°C
with 2 U of E. coli RNaseH to avoid RNA contamination
of cDNA, according to the manufacturer's protocol (Life
Technologies Ltd., U.K.).
PCR assays were carried out in a PTC-200 programmable
thermal controller (MJ Research Inc., U.S.A.); 1 µl of
cDNA was amplified in a total volume of 10 µl contain-
ing. The general PCR protocol included 1x PCR reaction
buffer, 2.5 mM MgCl2, 0.4 mM dNTPs, and 0.6 U Plati-
num Taq DNA polymerase (Life Technologies Ltd., U.K.),
with 30 pmol of each primer set. Cycling parameters were
as follows: 3 min for initial denaturation at 94°C; 30 sec
at 94°C, 30 sec at 58°C for primer annealing, 40 sec at
72°C for primer extension, these steps were repeated for
35 cycles; final extension step at 72°C for 10 min. β2-
microglobulin was used as an internal control in all PCR
reactions.
PCR products were analysed by 8% polyacrylamide gel
electrophoresis (29:1 ratio acrylamide/bis-acrylamide)
and silver stained. Gels were scanned on an Agfa Snap-
Scan 1212 u (Agfa-Gevaert N.V., Belgium). The integrated
density of the bands was used as quantitative parameter
and was calculated by digital image analysis (Scion
image). The ratio of the integrated density of each gene
divided by that of β2-microglobulin was used to quantify
the results.
The oligonucleotide primers used in the study were: β2-
microglobulin;Forward (F):
TCCAACATCAACATCTTGGT,
β2-microglobulin;Reverse (R):
TCCCCCAAATTCTAAGCAGA,
TGF-β1;F: ATGAACTCATTCAGTCACCATAGC,
TGF-β1;R: CTATCCCCCACTAAAGCAGG,
VEGF;F: ACGATCGATACAGAAACCACG,
VEGF;R: CTCTGCGCAGAGTCTCCTCT,
bFGF;F: GCCACATCTAATCTCATTTCACA,
bFGF;R: CTGGGTAACAGCAGATGCAA.
Statistical analysis
Data are reported as mean ± SEM. Initial statistical com-
parison of the mRNA expression results between the CAD
and the noCAD (control) groups was performed utilizing
the Mann Whitney test [18]. Subsequent analysis between
noCAD, CAD SA (stable angina) and CAD UA (unstable
ungina) groups for statistically significant differences in
enumerative data was performed with the use of the X2
test. Analysis between groups for continuous variables
such as age, number of diseased vessels and % of lym-
phocytes was performed with one-way ANOVA. The
expression of VEGF, bFGF and TGF-β1 mRNA was com-
pared between the groups noCAD, CAD SA (stable
angina) and CAD UA (unstable ungina) by ANCOVA with
age, number of diseased vessels, family history of heart
disease, diabetes, smoking, hypertension, and hypercho-
lesterolaemia as covariates. Bonferroni post hoc compari-
sons were performed to compare the adjusted levels of
VEGF, bFGF and TGF-β1 between the 3 groups.
Results
Quantitation of the mRNA for VEGF, bFGF and TGF-β1 in 
peripheral monocytes and lymphocytes
A representative semi-quantitative RT-PCR assay demon-
strating a range of differences in the production of VEGF,
bFGF and TGF-β1 mRNA in 5 different donors is shown in
Figure 1. The quantification and statistical evaluation of
the mRNA expression results (Mann Whitney test) for the
CAD and the noCAD (control) groups showed no signifi-
cant difference for any of the above factors. Stepwise
regression analysis of the expression of VEGF with CAD-
related clinical parameters (angina, age, number of dis-
eased vessels, family history of heart disease, diabetes,
smoking, hypertension, and hypercholesterolaemia)
revealed a highly significant association to the angina
parameter (R = 0.5, p = 0.003).
In order to investigate further the relation of the mRNA
expression of VEGF, bFGF and TGF-β1 with the angina
parameter we divided our patients in the following
groups: noCAD(control), CAD SA (CAD with stable
angina), CAD UA (CAD with unstable angina) and pro-
ceeded with the statistical evaluation alone or in coopera-
tion with other clinical parameters. The profile of the
donors in the noCAD, CAD SA and CAD UA groups with
regard to sex, levels of uric acid, hypertension, cigarette
smoking, diabetes, family history, hypercholesterolaemia
and number of diseased vessels is given in Table 1. Lym-
phocyte counts for the donors are shown in Table 2. There
was no statistically significant difference between the 3
patient groups in any of these variables.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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The statistical analysis of the mRNA quantification results
revealed a significant difference in the basal level expres-
sion between the three patient groups for macrophage
VEGF and bFGF. No statistically significant differences
were detected for macrophage TGF-β1 and lymphocyte
VEGF, bFGF and TGF-β1.
A summary of the results is shown in Table 3. In periph-
eral macrophages for donors with no coronary arterial
disease (noCAD) the mean VEGF/β2M ratio was 32.13+/-
8.38, for CAD patients with stable angina the mean VEGF/
β2M ratio was 152.07+/-50.63 and for CAD patients with
unstable angina the mean VEGF/β2M ratio was 23.86+/-
6.7. The respective mean values of bFGF/β2M ratio in the
above patient groups were: noCAD 16.73+/-8, CAD SA
85.98+/-25.26 and CAD UA 5.3+/-1.63. In the lym-
phocyte cell fraction the respective mean values of VEGF/
β2M ratio in the above patient groups were: noCAD
4.31+/-3.72, CAD SA 22.66+/-14.16 and CAD UA 1.62+/-
1.62.
Table 1: The characteristics of patients
Covariate Control CAD SA1 CAD UA2 X2 F3 p
n1 7 1 9 1 7
Male sex, % 59 89.5 70.6 4.45 0.100
Uric acid, % 11.7 26.3 11.7 1.83 0.400
(7 mg/dl)
Hypertension, % 53 79 53 2.95 0.229
(S.B.P.4 ≥ 160 mm Mg, D.B.P.5 > 90 mm Mg)
Cigarette smoking, % 4 15 35 31 . 0 9 0 . 5 7 8
Diabetes, % 23.5 52.6 41 3.2 0.201
(≥ 126 mg/dl6,≥ 200 mg/dl7)
Family history, % 35 37 53 1.36 0.507
Hypercholesterolaemia, % 47 68 76 3.43 0.179
(LDL ≥ 160 mg/dl8, LDL ≥ 130 mg/dl9, LDL ≥ 100 mg/dl10)
No. of diseased vessels (mean) 0 2.1 ± 0.87 1.9 ± 0.82 0.332 0.568
1:Coronary Artery disease, Stable Angina. 2:Coronary Artery disease, Unstable Angina. 3:ANOVA analysis of the number of diseased vessels from 
CAD SA and CAD UA patient groups. 4:Systolic Blood Pressure. 5:Diastolic Blood Pressure. 6:two separate values of fasting blood glucose. 7:two 
random values of blood glucose. 8:for patient without any artery risk factors for Coronary Artery Disease. 9:for patient with one known risk factor 
for Coronary Artery Disease. 10:for patient with known Coronary Artery Disease.
Table 2: Haematological parameters
Control CAD SA 1 CAD UA 2 F3 P
n1 0 91 2
Neutrophiles (mean) 0,617 0,689 0,559 1,066 0.354
Lymphocytes (mean) 0,293 0,226 0,334 0,845 0,436
Monocytes (mean) 0,053 0,062 0,078 0,608 0,551
1 Coronary artery disease Stable Angina. 2 Coronary artery disease Unstable Angina. 3 Analysis ANOVA
Acrylamide gel electrophoresis of RT-PCR products Figure 1
Acrylamide gel electrophoresis of RT-PCR products. 
RT-PCR products from 5 random patients demonstrating the 
interindividual differences in mRNA expression of VEGF, 
bFGF, and TGF-β1 in peripheral monocytes/macrophages. 
The RT-PCR and the mRNA semi-quantification for each fac-
tor were performed as described in the Methods section.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
Page 6 of 11
(page number not for citation purposes)
The effect of glucose and statins in the expression of VEGF 
and bFGF
We selected 2 independent healthy male donors, age of 27
and 23 years, with no prior history of atherosclerosis or
diabetes. These samples were processed in an identical
fashion to those from patients from the catheterization
laboratory. The intra assay variability of the mRNA meas-
urements of our in vitro short term culture system was
assessed by measuring the VEGF and bFGF mRNA in trip-
licate cultures each. For donor 1 the mean VEGF/β2M
ratio was 97.5+/-1.53 and bFGF/β2M ratio 54.62+/-5.19.
For donor 2 the mean VEGF/β2M ratio was 45.47+/-4.55
and bFGF/β2M ratio 18.87+/-2.37.
Furthermore we analyzed in the above model the effect of
high glucose levels found in diabetic individuals and stat-
ins found in the medication of all our patients on the
mRNA levels of VEGF and bFGF during a 48 hour period.
We isolated a blood sample from healthy donor 1 in an
identical fashion to those from patients from the catheter-
ization laboratory and set cultures with appropriate con-
centrations of glucose, statin and glucose+statin. After the
1 hour attachment period the cultures were harvested at
specific time intervals (30 min, 1 h, 2, 4, 24 h, 48 h) and
the mRNA of VEGF and bFGF was quantified. The results
show a gradual time dependent decrease of both mRNA
levels (Figure 2) which was not affected by glucose or sta-
tin. The experiment was repeated with a different donor
and the results were similar. Although the initial values of
bFGF and VEGF differed slightly, consistent with the
donor variation, the trend for decline of expression was
the same. These results should be evaluated in the context
of our in vitro system since in vivo gene expression is not
always the same.
Statistical evaluation of the results between different 
patient groups
The mRNA quantification revealed a significant difference
in the basal level expression between the three groups for
macrophage VEGF and bFGF(Figure 3A,3C). No
statistically significant differences were detected for mac-
rophage TGF-β1 and lymphocyte VEGF, bFGF and TGF-
β1.
The difference in the macrophage VEGF expression
between noCAD control patients and CAD SA patients
was statistically significant (p = 0.041), as was the differ-
ence between patients with CAD SA and CAD UA (p =
0.024) (Figure 3A). There was no statistical difference
between the macrophage VEGF expression of noCAD and
CAD UA patients (p = 0.445) (Figure 3A). Similarly, for
macrophage bFGF, the difference in expression between
patients with CAD SA and CAD UA was highly statistically
significant (p  = 0.005) as was the difference between
patients with CAD SA and noCAD (p = 0.022) (Figure
3C). There was no statistical difference between noCAD
and CAD UA patients (p = 0.160) (Figure 3C). No statisti-
cally significant differences were detected for macrophage
TGF-β1 and lymphocyte VEGF (Figure 3E), bFGF and
TGF-β1 in any of the patient groups.
The mRNA expression data from the 3 groups were sub-
jected to ANCOVA using the variables age, sex, prior
myocardial infarction, hypertension, family history,
hypercholesterolaemia, cigarette smoking, diabetes, and
number of diseased vessels as covariates. The simple anal-
ysis of variance gave a significant difference between the
three groups for macrophage VEGF (p = 0.011) (Figure
3B) and macrophage bFGF (p = 0.002) (Figure 3D). Dia-
betes was the only covariate found to influence greatly the
variance improving considerably the significance of our
model both for VEGF (p = 0.001) (Figure 3B) and bFGF (p
= 0.000) (Figure 3D). Bonferroni post hoc comparison
between the groups noCAD and CAD SA and between the
groups CAD SA and CAD UA revealed a statistically signif-
icant difference in VEGF expression (p = 0.021 and p =
0.011 respectively). No significant difference was found
between the groups with noCAD and CAD UA. Bonfer-
roni post hoc comparison in bFGF expression between the
groups CAD SA – CAD UA and noCAD – CAD SA revealed
a statistically significant difference (p = 0.003) and (p =
0.016) respectively. No significant difference of bFGF was
found between the groups noCAD – CAD UA (p = 0.843).
Pearson two tailed correlation of VEGF and bFGF expres-
sion was found to be highly significant (p < 0.001).
Table 3: Summary of the results on VEGF and bFGF expression in monocytes (Mf) and lymphocytes (Ly)
No CAD CADSA CADUA
VEGF/β2M Mf 32.13+/-8.38 152.07+/-50.63 23.86+/-6.7
bFGF/β2M Mf 16.73+/-8 85.98+/-25.26 5.3+/-1.63
VEGF/β2M Ly 4.31+/-3.72 22.66+/-14.16 1.62+/-1.62
Data are presented as mean ± SEM (standard error of the mean). The values represent the VEGF/β2-microglobulin and bFGF/β2-microglobulin 
ratios which were calculated by the optical integrated density of each gene divided by that β2-microglobulin.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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Discussion
The present study provides evidence on the relationship of
the expression of VEGF, bFGF and TGF-β1 in the periph-
eral monocyte and lymphocyte cell populations from
patients with coronary artery disease. The mRNA quantifi-
cation revealed a significant increase of the basal level
expression for macrophage VEGF and bFGF in the CAD SA
patient group compared to the noCAD and CAD UA
groups, which was highly dependent on the diabetic sta-
tus of the population. Our findings contribute to the
understanding of the role of VEGF, bFGF and TGF-β1 in
cardiovascular disease.
A recent study on the hypoxic induction of VEGF reported
a low level of VEGF expression from monocytes of athero-
sclerotic donors after 24 hours of culture [9]. Aiming to
follow the kinetics of the mRNA expression of VEGF and
bFGF during a 48 hour culture period we set up a control
experiment with monocytes isolated from a healthy
donor. We observed that the expression of both genes
declined in a time dependent fashion reaching the lowest
levels at 24 to 48 hours. The result explained the consist-
ently low values reported previously [9]. Our measure-
ments of the mRNA profile were performed immediately
after cell isolation in order to ensure the representative
mirroring of the in vivo condition. All samples were
Analysis of the effect of glucose and fluvastatin on the kinetics of mRNA expression of VEGF (–▪–) and bFGF (–•–) in normal  monocytes/macrophages during a 48 hour in vitro treatment period Figure 2
Analysis of the effect of glucose and fluvastatin on the kinetics of mRNA expression of VEGF (–▪–) and bFGF (–
•–) in normal monocytes/macrophages during a 48 hour in vitro treatment period. A, no treatment. B, treatment 
with glucose (6 mg/ml). C, treatment with fluvastatin (1 µM). D, treatment with glucose and Fluvastatin. The y-axis represents 
the VEGF/β2-microglobulin and bFGF/β2-microglobulin ratio of the integrated density respectively.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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Boxplots of the expression of VEGF and bFGF Figure 3
Boxplots of the expression of VEGF and bFGF. Distribution boxplot of the expression of VEGF in monocytes/macro-
phages (A, B), bFGF in monocytes /macrophages (C, D) and VEGF in lymphocytes (E, F). The boxplots A, C and E demonstrate 
the expression in the control, CAD SA and CAD UA group. The boxplots B, D and F demonstrate the expression in the above 
groups classified for diabetes. The y-axis values represent the VEGF/β2-microglobulin and bFGF/β2-microglobulin ratios 
accordingly. The ratios were calculated by the optical integrated density of each gene divided by that of β2-microglobulin. The 
optical integrated density was calculated by digital image analysis (Scion image) of acrylamide gel electrophoresis of the RT-PCR 
products. Mf: macrophages, Ly: non-adherent lymphocyte fraction, ns: non-significant.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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treated exactly the same way to ensure that the effect of
cell handling and isolation, if any, was uniform.
All the patients in our study received standard medication
which among other compounds included statins. Statins
have been reported to influence the surface phenotype of
peripheral lymphocytes [16]. To determine the effect of
fluvastatin on the mRNA expression of bFGF and VEGF in
monocytes of a healthy donor we performed kinetic anal-
ysis. We observed no significant effect on VEGF or bFGF
during the 48 hour in vitro fluvastatin treatment. Glucose
has been reported to be able to influence macrophage dif-
ferentiation state in general and specifically CD36
through direct effect on the mRNA level [19]. Since our
major finding is related to diabetic individuals usually
exhibiting high glucose levels, we evaluated the short term
effect of glucose on monocytes of a healthy donor simi-
larly to the above kinetic analysis. We observed no signif-
icant deviation from the untreated mRNA levels for VEGF
and bFGF during a 48 hour period after treatment with
glucose alone or in combination with fluvastatin.
VEGF and bFGF have been isolated in human cardiac tis-
sue where increased levels were observed among patients
with acute myocardial infraction [20] and unstable angina
pectoris [21]. Presence of VEGF and bFGF has been dem-
onstrated in atherosclerotic lesions produced mainly by
macrophages [22,23]. Furthermore it was reported that
VEGF can induce migration and activation of monocytes
through its receptor flt-1 [24], up regulation of adhesion
molecules on endothelial cells [25] and secretion of
monocyte chemoattractant protein 1 (MCP-1) [26].
Detection of VEGF in the serum in atherosclerotic patients
requires the existence of an appropriate source producing
it in high amount. Our results demonstrate that in CAD
the VEGF, bFGF and TGF-β1 are not systematically pro-
duced by peripheral lymphocytes or monocytes. Expres-
sion of the VEGF and bFGF gene was restricted to the
monocyte population in the CAD patient group with sta-
ble angina. Corroborating with our results a previous
study demonstrated that patients with stable angina pec-
toris had higher amounts of serum VEGF compared to old
myocardial infraction and control patients [27]. In
patients suffering from stable effort induced angina pec-
toris, repeated myocardial ischemic stimuli can be
expected to continuously sustain collateral growth and
remodeling and display increased amounts of activated
macrophages in the periphery primed to produce ang-
iogenic factors. The high level of serum VEGF and bFGF
reported in other stages of atherosclerosis should be
accredited to other potential sites of production like the
atherosclerotic lesion itself. The serum VEGF concentra-
tions in the early stage of myocardial infarction was
reported to be high reaching maximum levels between
day 7–14 post MI. [28,29]. Elevated VEGF production in
the serum has also been detected in diabetic retinopathy
[30], hyperlipidaimia [31] and hypertention [32]
asymptomatic for atherosclerosis. Diabetes is a negative
prognostic indicator for patients with coronary arterial
disease. Our study revealed a striking restriction of VEGF
and bFGF mRNA expression in the diabetic sub-group of
the atherosclerosis patient group with stable angina pec-
toris while the non diabetic sub-group displayed levels
similar to the normal group. In agreement with our obser-
vations a recent study reported that diabetic individuals
with atherosclerosis display relatively increased levels of
serum VEGF [33] but they did not test stable angina pec-
toris as a covariate. A factor related to the diabetic condi-
tion (unbalanced glucose levels, defective insulin
regulation, etc) in cooperation with the myocardial
ischemia could be responsible for the high levels of VEGF
and bFGF observed in the diabetic patients (CAD SA). In
agreement a recent study demonstrated in vivo a direct
effect of the insulin induced modulation of the level of
glucose on the serum levels of VEGF [34]. The fact that the
CAD UA groups showed low levels of expression is inter-
esting and could be attributed to the migration of mono-
cyte producers from the periphery to the sites of ongoing
tissue damage. The numerous biochemical and metabolic
pathways postulated to have a causal role in the pathogen-
esis of diabetic vascular disease can be summarized to the
following hypothesis: either the effect of increased reduc-
tive or oxidative stress to the cell, or activation of numer-
ous protein kinase pathways, particularly protein kinase C
and mitogen-activated protein kinases, induces growth
factor expression among which the most important is
VEGF. Our contribution to the proposed model is that the
induction of VEGF in the periphery could require precon-
ditioning of the monocytes which is performed during the
chronic myocardial ischemic condition observed in the
CAD SA group.
Collateral vessel formation termed arteriogenesis usually
follows severe atherosclerosis. Arteriogenesis is severely
reduced in patients with diabetes mellitus [35]. Recent
studies showed that arteriogenesis requires active migra-
tion of peripheral monocytes to the site of ischemia and
interaction with epithelium of the arteriole [8]. In addi-
tion it is known that the migration of monocytes is medi-
ated through the action of VEGF and its receptor Flt-1
[36,37]. Trying to identify the molecular abnormality
Waltenberger et al. demonstrated that in diabetics mono-
cytes have a functional defect: they do not respond to
migratory signals from VEGF although their flt-1 receptor
level is normal and the intracellular pathway is functional
[10]. Our results demonstrate that monocytes from dia-
betic CAD SA patients express very high amounts of VEGF
mRNA. We propose that the migratory defect could be
caused by the increased autocrine VEGF production of theJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/6
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peripheral monocytes. In fact Waltenberger et al [10]
included a control experiment demonstrating that mono-
cytes migrate only when they encounter a gradient of
VEGF concentration. Although additional experiments are
necessary to evaluate the monocyte migratory responses
in our patients, it is tempting to speculate that in diabetic
patients of the CAD SA group, the VEGF gradient is dis-
turbed causing defective collateral vessel formation. A
direct consequence of this model is that any thought of
intravenous administration of VEGF for a therapeutic
intervention should be carefully examined since infusion
of VEGF could derange monocyte migratory responses
and lead to impaired collateral vessel development.
Conclusions
We observed a significant increase of the basal level
expression for macrophage VEGF and bFGF in the CAD SA
(stable angina) patient group compared to the noCAD
(control) and CAD UA (unstable angina) groups. The
increase was highly dependent on the diabetic status of
the population. Our findings contribute to the under-
standing of the increased risk of atherosclerosis as well as
to the impaired collateral vessel formation which is well
documented for the diabetic CAD patients.
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